Anamorelin - CAS 249921-19-5
Catalog number: 249921-19-5
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C31H42N6O3
Molecular Weight:
546.7
COA:
Inquire
Targets:
GHSR
Description:
Anamorelin, also known as RC-1291 or ONO-7643, is the orally bioavailable, small-molecule ghrelin mimetic with appetite-stimulating and anabolic activities. Anamorelin binds to and stimulates the growth hormone secretagogue receptor (GHSR) centrally, thereby mimicking the appetite-stimulating and growth hormone-releasing effects of grhelin. Stimulation of GHSR may also reduce the production of the pro-inflammatory cytokines TNF-alpha and interleukin-6, which may play a direct role in cancer-related loss of appetite.
Purity:
>98%
Synonyms:
RC-1291; ONO-7643; RC1291; ONO7643; RC 1291; ONO 7643
MSDS:
Inquire
InChIKey:
VQPFSIRUEPQQPP-MXBOTTGLSA-N
InChI:
InChI=1S/C31H42N6O3/c1-30(2,32)28(39)34-26(18-23-20-33-25-15-10-9-14-24(23)25)27(38)37-17-11-16-31(21-37,29(40)36(5)35(3)4)19-22-12-7-6-8-13-22/h6-10,12-15,20,26,33H,11,16-19,21,32H2,1-5H3,(H,34,39)/t26-,31-/m1/s1
Canonical SMILES:
CC(C)(C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)N3CCCC(C3)(CC4=CC=CC=C4)C(=O)N(C)N(C)C)N
1.Evidence for partial pharmaceutical reversal of the cancer anorexia-cachexia syndrome: the case of anamorelin.
Anker SD1, Coats AJ2, Morley JE3. J Cachexia Sarcopenia Muscle. 2015 Dec;6(4):275-7. doi: 10.1002/jcsm.12063. Epub 2015 Aug 30.
A major component of the cancer anorexia-cachexia syndrome is a decline in food intake. Up until now none of the drugs that improve appetite also improve skeletal muscle. Recent studies have suggested that the oral ghrelin-analog, anamorelin, increased food intake and muscle mass. Unfortunately, it does not increase muscle power. Its regulatory future is uncertain, although it has important clinical effects.
2.Simplifying and expanding the screening for peptides <2 kDa by direct urine injection, liquid chromatography, and ion mobility mass spectrometry.
Thomas A1, Görgens C1, Guddat S1, Thieme D2, Dellanna F3, Schänzer W1, Thevis M1. J Sep Sci. 2016 Jan;39(2):333-41. doi: 10.1002/jssc.201501060. Epub 2015 Dec 15.
The analysis of low-molecular-mass peptides in doping controls has become a mandatory aspect in sports drug testing and, thus, the number of samples that has to be tested for these analytes has been steadily increasing. Several peptides <2 kDa with performance-enhancing properties are covered by the list of prohibited substances of the World Anti-Doping Agency including Desmopressin, LH-RH, Buserelin, Triptorelin, Leuprolide, GHRP-1, GHRP-2, GHRP-3, GHRP-4, GHRP-5,GHRP-6, Alexamorelin, Ipamorelin, Hexarelin, ARA-290, AOD-9604, TB-500 and Anamorelin. With the presented method employing direct urine injection into a liquid chromatograph followed by ion-mobility time-of-flight mass spectrometry, a facile, specific and sensitive assay for the aforementioned peptidic compounds is provided. The accomplished sensitivity allows for limits of detection between 50 and 500 pg/mL and thus covers the minimum required performance level of 2 ng/mL accordingly.
3.Mechanisms of anorexia-cachexia syndrome and rational for treatment with selective ghrelin receptor agonist.
Esposito A1, Criscitiello C1, Gelao L1, Pravettoni G2, Locatelli M1, Minchella I1, Di Leo M1, Liuzzi R1, Milani A1, Massaro M1, Curigliano G3. Cancer Treat Rev. 2015 Nov;41(9):793-7. doi: 10.1016/j.ctrv.2015.09.002. Epub 2015 Sep 11.
Cancer cachexia is a multi-organ, multifactorial and often irreversible syndrome affecting many patients with cancer. Cancer cachexia is invariably associated with weight loss, mainly from loss of skeletal muscle and body fat, conditioning a reduced quality of life due to asthenia, anorexia, anaemia and fatigue. Treatment options for treating cancer cachexia are limited. The approach is multimodal and may include: treatment of secondary gastrointestinal symptoms, nutritional treatments, drug, and non-drug treatments. Nutritional counselling and physical training may be beneficial in delaying or preventing the development of anorexia-cachexia. However, these interventions are limited in their effect, and no definitive pharmacological treatment is available to address the relevant components of the syndrome. Anamorelin is a first-in-class, orally active ghrelin receptor agonist that binds and stimulates the growth hormone secretagogue receptor centrally, thereby mimicking the appetite-enhancing and anabolic effects of ghrelin.
4.An open-label clinical trial of the effects of age and gender on the pharmacodynamics, pharmacokinetics and safety of the ghrelin receptor agonist anamorelin.
Leese PT1, Trang JM2, Blum RA3, de Groot E4. Clin Pharmacol Drug Dev. 2015 Mar;4(2):112-120. Epub 2015 Feb 9.
PURPOSE: To assess the effect of age and gender on the pharmacokinetics (PK) of the ghrelin receptor agonist anamorelin.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related GHSR Products


CAS 158861-67-7 Pralmorelin

Pralmorelin
(CAS: 158861-67-7)

Pralmorelin is an agonist of ghrelin/growth hormone secretagogue (GHS) receptor. It is marketed by Kaken Pharmaceutical in Japan in a single-dose formulation fo...

CAS 193273-69-7 Capromorelin Tartrate

Capromorelin Tartrate
(CAS: 193273-69-7)

Capromorelin Tartrate is the Tartrate salt of Capromorelin, also known as CP-424,391, which is an orally active, potent growth hormone secretagogue receptor (GH...

CAS 1088543-62-7 AZP-531

AZP-531
(CAS: 1088543-62-7)

AZP-531, an analogue of unacylated ghrelin, was designed to improve glycaemic control and reduce weight with potential for the treatment of Prader-Willi syndrom...

CAS 861998-00-7 Anamorelin HCl

Anamorelin HCl
(CAS: 861998-00-7)

Anamorelin, also known as RC-1291 or ONO-7643, is the orally bioavailable, small-molecule ghrelin mimetic with appetite-stimulating and anabolic activities. An...

PF-5190457
(CAS: 1334782-79-4)

PF-5190457 is a selective Growth hormone secretagogue receptor inverse agonist and it can increase insulin secretion in glucose-stimulated human islets. No rece...

CAS 249921-19-5 Anamorelin

Anamorelin
(CAS: 249921-19-5)

Anamorelin, also known as RC-1291 or ONO-7643, is the orally bioavailable, small-molecule ghrelin mimetic with appetite-stimulating and anabolic activities. An...

CAS 339539-92-3 Anamorelin Fumarate

Anamorelin Fumarate
(CAS: 339539-92-3)

Anamorelin hydrochloride is the orally bioavailable hydrochloride salt of a synthetic, small-molecule ghrelin mimetic with appetite-stimulating and anabolic act...

CAS 1621175-65-2 TC-G-1008

TC-G-1008
(CAS: 1621175-65-2)

TC-G-1008, also known as GPR39-C3, is a potent and orally available GPR39 agonist (EC50= 0.4 and 0.8 nM for rat and human receptors respectively) with great sel...

Chemical Structure

CAS 249921-19-5 Anamorelin

Quick Inquiry

Verification code

Featured Items